{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:05:17Z","timestamp":1793505917884,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016062","name":"Metakids Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["0915016191023"],"award-info":[{"award-number":["0915016191023"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.gim.2026.102578","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:28:03Z","timestamp":1776101283000},"page":"102578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antibody formation and efficacy of enzyme replacement therapy in adults with Pompe disease: Unlocking long-term insights"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9160-0202","authenticated-orcid":false,"given":"Maudy T.M.","family":"Theunissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-3108","authenticated-orcid":false,"given":"Imke A.M.","family":"Ditters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9098-1356","authenticated-orcid":false,"given":"Harmke A.","family":"van Kooten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2584-3357","authenticated-orcid":false,"given":"Pieter A.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8091-263X","authenticated-orcid":false,"given":"Johanna M.P.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Hoogeveen-Westerveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin H.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3359-1324","authenticated-orcid":false,"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9161-3301","authenticated-orcid":false,"given":"Nadine A.M.E.","family":"van der Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.gim.2026.102578_bib1","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.gim.2026.102578_bib2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(24)00518-0","article-title":"Clinical insights in enzyme replacement therapy for metabolic storage disorders: lessons from Pompe disease","volume":"24","author":"van der Beek","year":"2025","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.gim.2026.102578_bib3","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/humu.23854","article-title":"Extension of the Pompe mutation database by linking disease-associated variants to clinical severity","volume":"40","author":"Ni\u00f1o","year":"2019","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.gim.2026.102578_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/humu.24148","article-title":"Update of the Pompe variant database for the prediction of clinical phenotypes: novel disease-associated variants, common sequence variants, and results from newborn screening","volume":"42","author":"de Faria","year":"2021","journal-title":"Hum Mutat"},{"issue":"9646","key":"10.1016\/j.gim.2026.102578_bib5","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.gim.2026.102578_bib6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.gim.2026.102578_bib7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41431-020-00752-2","article-title":"Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience","volume":"29","author":"Ni\u00f1o","year":"2021","journal-title":"Eur J Hum Genet"},{"issue":"1-2","key":"10.1016\/j.gim.2026.102578_bib8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cccn.2005.05.025","article-title":"Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease","volume":"361","author":"Umapathysivam","year":"2005","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/j.gim.2026.102578_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.gim.2026.102578_bib10","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","article-title":"Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years","volume":"259","author":"Angelini","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.gim.2026.102578_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1750-1172-7-73","article-title":"Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study","volume":"7","author":"de Vries","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.gim.2026.102578_bib12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","article-title":"36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy","volume":"35","author":"Regnery","year":"2012","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"10.1016\/j.gim.2026.102578_bib13","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","article-title":"Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa","volume":"107","author":"van der Ploeg","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.gim.2026.102578_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study","volume":"8","author":"G\u00fcng\u00f6r","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.gim.2026.102578_bib15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","article-title":"Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.gim.2026.102578_bib16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.gim.2026.102578_bib17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","article-title":"Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II","volume":"33","author":"Bembi","year":"2010","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"10.1016\/j.gim.2026.102578_bib18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10545-014-9751-2","article-title":"Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease","volume":"38","author":"van der Meijden","year":"2015","journal-title":"J Inherit Metab Dis"},{"issue":"23","key":"10.1016\/j.gim.2026.102578_bib19","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","article-title":"Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study","volume":"89","author":"Kuperus","year":"2017","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.gim.2026.102578_bib20","doi-asserted-by":"crossref","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.gim.2026.102578_bib21","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1021\/acs.analchem.5b00169","article-title":"Absolute quantification of the total and antidrug antibody-bound concentrations of recombinant human \u03b1-glucosidase in human plasma using protein G extraction and LC-MS\/MS","volume":"87","author":"Bronsema","year":"2015","journal-title":"Anal Chem"},{"issue":"2","key":"10.1016\/j.gim.2026.102578_bib22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease","volume":"38","author":"van Gelder","year":"2015","journal-title":"J Inherit Metab Dis"},{"issue":"8","key":"10.1016\/j.gim.2026.102578_bib23","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gim.2026.102578_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2026.102578_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13023-022-02175-2","article-title":"Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease","volume":"17","author":"van Kooten","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.gim.2026.102578_bib26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.gim.2026.102578_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","article-title":"The impact of antibodies in late-onset Pompe disease: a case series and literature review","volume":"106","author":"Patel","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2026.102578_bib28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/gim.2016.70","article-title":"Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy","volume":"19","author":"de Vries","year":"2017","journal-title":"Genet Med"},{"issue":"9","key":"10.1016\/j.gim.2026.102578_bib29","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/biom13091414","article-title":"Are anti-rhGAA antibodies a determinant of treatment outcome in adults with late-onset Pompe disease? A systematic review","volume":"13","author":"Ditters","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.gim.2026.102578_bib30","article-title":"Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"issue":"16","key":"10.1016\/j.gim.2026.102578_bib31","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1212\/WNL.0000000000003847","article-title":"Reference values for developing responsive functional outcome measures across the lifespan","volume":"88","author":"McKay","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.gim.2026.102578_bib32","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1164\/rccm.166.4.518","article-title":"ATS\/ERS Statement on respiratory muscle testing","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.gim.2026.102578_bib33","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.gim.2026.102578_bib35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40259-023-00609-2","article-title":"Home-based infusion of alglucosidase alfa can safely be implemented in adults with late-onset Pompe disease: lessons learned from 18,380 infusions","volume":"37","author":"Ditters","year":"2023","journal-title":"BioDrugs"},{"issue":"12","key":"10.1016\/j.gim.2026.102578_bib36","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/cpdd.1314","article-title":"Pharmacokinetics of alglucosidase alfa manufactured at the 4000-L scale in participants with Pompe disease: a phase 3\/4 open-label study","volume":"12","author":"Nicolas","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.gim.2026.102578_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/srep36182","article-title":"Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients","volume":"6","author":"Masat","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.gim.2026.102578_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107611","article-title":"Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: an experience from the French Pompe Registry","volume":"139","author":"Lessard","year":"2023","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2026.102578_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13023-019-1039-z","article-title":"Effects of immunomodulation in classic infantile Pompe patients with high antibody titers","volume":"14","author":"Poelman","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.gim.2026.102578_bib40","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16383","article-title":"Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024","volume":"31","author":"Schoser","year":"2024","journal-title":"Eur J Neurol"},{"issue":"12","key":"10.1016\/j.gim.2026.102578_bib41","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (Comet): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.gim.2026.102578_bib42","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1212\/WNL.0000000000200746","article-title":"Long-term safety and efficacy of avalglucosidase Alfa in patients with late-onset Pompe disease","volume":"99","author":"Dimachkie","year":"2022","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.gim.2026.102578_bib43","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.gim.2026.102578_bib44","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1007\/s00415-024-12236-0","article-title":"104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)","volume":"271","author":"Schoser","year":"2024","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.gim.2026.102578_bib45","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2023.0552","article-title":"Efficacy and safety of avalglucosidase Alfa in patients with late-onset Pompe disease after 97 weeks: a phase 3 randomized clinical trial","volume":"80","author":"Kishnani","year":"2023","journal-title":"JAMA Neurol"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360026008968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360026008968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:24:59Z","timestamp":1786663499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360026008968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1098360026008968"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2026.102578","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody formation and efficacy of enzyme replacement therapy in adults with Pompe disease: Unlocking long-term insights","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2026.102578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.","name":"copyright","label":"Copyright"}],"article-number":"102578"}}